Abiopharma

🔍 ANGEL STEPHEN F (Director)

Company: LINDE PLC (LIN)

Report Date: 2026-01-20

Detailed Transactions and Holdings:

• Acquired 7,249 shares of Ordinary Shares (Direct)
  Date: 2026-01-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 462,791.08 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,552 shares of Ordinary Shares at $440.04 per share (Direct)
  Date: 2026-01-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 460,238.81 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-01-20 | Code: H | nature_of_ownership: 2010 Descendants Trust | shares_owned_after: 71,029.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-01-20 | Code: H | nature_of_ownership: 2012 Descendants Trust | shares_owned_after: 20,517.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-01-20 | Code: H | nature_of_ownership: In trust for children | shares_owned_after: 2,268.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-01-20 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 11,226.62
• Sold 7,249 shares of Deferred Stock Units (Derivative)
  Date: 2026-01-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 102,579.02 | transaction_form_type: 4 | Footnotes: F16, F17, F17
• Holds 1,030 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 1,029.66 | Footnotes: F3, F3, F3
• Holds 11,620 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 11,619.73 | Footnotes: F4, F4, F4
• Holds 11,514 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 11,513.51 | Footnotes: F5, F5, F5
• Holds 11,529 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 11,528.59 | Footnotes: F6, F6, F6
• Holds 24,426 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 24,425.65 | Footnotes: F7, F7, F7
• Holds 31,777 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 31,777.47 | Footnotes: F8, F8, F8
• Holds 46,459 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 46,458.92 | Footnotes: F9, F9, F9
• Holds 26,505 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-20 | Code: H | shares_owned_after: 26,667.97 | Footnotes: F10, F10, F10
• Holds 133,465 shares of Stock Options (right to buy) at $253.68 per share (Derivative)
  Date: 2026-01-20 | Code: H | Expires: 2031-03-08 | Exercise: 2022-03-08 | shares_owned_after: 133,465.00 | Footnotes: F11, F11, F11
• Holds 169,560 shares of Stock Options (right to buy) at $173.13 per share (Derivative)
  Date: 2026-01-20 | Code: H | Expires: 2030-03-09 | Exercise: 2021-03-09 | shares_owned_after: 169,560.00 | Footnotes: F12, F12, F12
• Holds 177,605 shares of Stock Options (right to buy) at $176.63 per share (Derivative)
  Date: 2026-01-20 | Code: H | Expires: 2029-03-20 | Exercise: 2020-03-20 | shares_owned_after: 177,605.00 | Footnotes: F13, F13, F13
• Holds 318,780 shares of Stock Options (right to buy) at $154.0 per share (Derivative)
  Date: 2026-01-20 | Code: H | Expires: 2028-02-27 | Exercise: 2019-02-27 | shares_owned_after: 318,780.00 | Footnotes: F14, F14, F14
• Holds 74,850 shares of Stock Options (right to buy) at $118.71 per share (Derivative)
  Date: 2026-01-20 | Code: H | Expires: 2027-02-28 | Exercise: 2018-02-28 | shares_owned_after: 74,850.00 | Footnotes: F15, F15

Footnotes:

• F1: Payout of Deferred Stock Units in ordinary shares pursuant to the Linde Compensation Deferral Plan.
• F2: Ordinary shares withheld to pay taxes on the Deferred Stock Unit payout.
• F3: The Restricted Stock Unit ("RSU") shall vest in full and payout in Ordinary Shares on a one-for-one basis one year after the March 7, 2025 date of grant, provided that the awardee serves on the Linde plc Board of Directors continuously through the vesting date, except under certain circumstances in which a pro-rata payout may be made.
• F4: Restricted Stock Units that will vest in full and payout on or about March 8, 2024 in Linde plc Ordinary Shares on a one-for-one basis.
• F5: Restricted Stock Units that have vested in full but whose payout has been deferred to a future date.
• F6: Restricted Stock Units granted March 20, 2019, that have vested in full but whose payout has been deferred to a future date.
• F7: Restricted Stock Units granted February 27, 2018, that have vested in full but whose payout has been deferred to a future date.
• F8: Restricted Stock Unit award granted February 28, 2017, that has vested in full but whose payout has been deferred to a future date.
• F9: Restricted Stock Units granted February 28, 2017, that have vested in full but whose payout has been deferred to a future date.
• F10: Restricted Stock Unit award granted February 23, 2016, that has vested in full but whose payout has been deferred to a future date.
• F11: This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022.
• F12: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.
• F13: This option vests over three years in three consecutive equal annual installments beginning on March 20, 2020.
• F14: This option vests over three years in three consecutive equal annual installments beginning on February 27, 2019.
• F15: This option vests over three years in three consecutive equal annual installments beginning on February 28, 2018.
• F16: Conversion to Linde plc Ordinary Shares is on a 1-for-1 basis
• F17: Deferred Stock Units acquired under the Linde Compensation Deferral Plan that will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Deferral Plan.